Adrenomedullin (AM) has vasodilatory, diuretic and natriuretic actions. Two molecular forms of AM circulate in human plasma : an active, mature form of AM (AM-m) and an intermediate, inactive, glycine-extended form of AM (AM-Gly). In the present study we investigated the pathophysiological significance of the two molecular forms of AM in plasma and urine in patients with acute myocardial infarction. We serially measured venous and arterial plasma levels and urinary excretion of AM-m, AM-Gly and total AM (Am-T ; l AM-mjAM-Gly) over 2 weeks using our recently developed immunoradiometric assay in 26 consecutive patients with acute myocardial infarction and in age-matched normal controls, and studied the relationships between AM levels and clinical parameters. Plasma AM-m, AM-Gly and AM-T levels were increased on admission in patients with acute myocardial infarction compared with age-matched normal controls. Levels of AM-m, AM-Gly and AM-T in plasma reached a peak 24 h after the onset of symptoms. Plasma AM-m, AM-Gly and AM-T levels were significantly correlated with plasma levels of brain natriuretic peptide and pulmonary arterial pressure. Plasma AM-Gly levels in the vein were similar to those in the artery, whereas plasma AM-m levels were significantly lower in the artery than in the vein. Urinary excretion of AM-m, AM-Gly and AM-T was also increased on admission, and reached a peak at 12 h after the onset of symptoms. Urinary excretion of AM-m and AM-Gly was significantly correlated with urinary sodium excretion. The AM-m/AM-T ratio was significantly higher in the urine than in the vein or artery. AM-m levels were significantly correlated with AM-Gly levels in both the urine and plasma ; however, there were no significant correlations between plasma and urinary AM levels. The results suggest that levels of both molecular forms of AM are increased in the urine as well as in the plasma in the acute phase of myocardial infarction. Since AM exerts potent cardiovascular and renal effects, increased concentrations of AM in plasma and urine in the acute phase of myocardial infarction may be involved in the defence mechanism against further elevations of peripheral and pulmonary vascular resistance and oliguria in acute myocardial infarction.
In the present study we investigated the pathophysiological significance of the two molecular forms of AM in plasma and urine in patients with acute myocardial infarction. We serially measured venous and arterial plasma levels and urinary excretion of AM-m, AM-Gly and total AM (Am-T ; l AM-mjAM-Gly) over 2 weeks using our recently developed immunoradiometric assay in 26 consecutive patients with acute myocardial infarction and in age-matched normal controls, and studied the relationships between AM levels and clinical parameters. Plasma AM-m, AM-Gly and AM-T levels were increased on admission in patients with acute myocardial infarction compared with age-matched normal controls. Levels of AM-m, AM-Gly and AM-T in plasma reached a peak 24 h after the onset of symptoms. Plasma AM-m, AM-Gly and AM-T levels were significantly correlated with plasma levels of brain natriuretic peptide and pulmonary arterial pressure. Plasma AM-Gly levels in the vein were similar to those in the artery, whereas plasma AM-m levels were significantly lower in the artery than in the vein. Urinary excretion of AM-m, AM-Gly and AM-T was also increased on admission, and reached a peak at 12 h after the onset of symptoms. Urinary excretion of AM-m and AM-Gly was significantly correlated with urinary sodium excretion. The AM-m/AM-T ratio was significantly higher in the urine than in the vein or artery. AM-m levels were significantly correlated with AM-Gly levels in both the urine and plasma ; however, there were no significant correlations between plasma and urinary AM levels. The results suggest that levels of both molecular forms of AM are increased in the urine as well as in the plasma in the acute phase of myocardial infarction. Since AM exerts potent cardiovascular and renal effects, increased concentrations of AM in plasma and urine in the acute phase of myocardial infarction may be involved in the defence mechanism against further elevations of peripheral and pulmonary vascular resistance and oliguria in acute myocardial infarction.
INTRODUCTION
Adrenomedullin (AM) is a 52-amino-acid peptide that was originally discovered in acid extracts from human pheochromocytoma [1] . Subsequent studies have demonstrated that AM has various physiological effects on the cardiovascular system, including vasodilatation [2, 3] , diuresis [4] , natriuresis [5] , inhibition of aldosterone secretion [6, 7] and increasing cardiac output [8, 9] . Plasma AM levels are increased in proportion to the severity of cardiovascular disease in conditions such as heart failure [10, 11] , hypertension [12, 13] , renal failure [12, 14] and pulmonary hypertension [15, 16] . These findings suggest that AM may participate in the regulation of cardiovascular and renal homoeostasis, and may be involved in the pathophysiology of cardiovascular and renal disease.
The human AM precursor consists of 185 amino acids with a putative signal peptide [17] . AM is produced from the AM precursor by a two-step enzymic reaction. First, the AM precursor is converted into C-terminally glycine-extended AM (AM-Gly), a 53-amino-acid peptide which represents an intermediate, inactive form of AM. Subsequently, inactive AM-Gly is converted into a mature, active form of AM (AM-m), a 52-amino-acid peptide with a C-terminal amide structure, by enzymic amidation. Recently Kitamura et al. [18] reported that the two molecular forms of AM, i.e. AM-m and AM-Gly, circulate in human blood.
Previous studies have reported that plasma AM levels are increased at an early stage in patients with acute myocardial infarction [19] [20] [21] . However, the relative proportions of these two molecular forms of plasma AM, as well as their production and clearance sites, the regulation of production and their pathophysiological significance in acute myocardial infarction patients remain unknown. In addition, it is reported that AM is present in human urine, and that AM levels are several times higher in urine than in plasma [22] , suggesting that urinary AM is produced in the kidney. However, whether urinary AM is elevated in acute myocardial infarction has never been studied.
In the present study, we explore the relative proportions, the production and clearance sites, the regulation of production and the pathophysiological significance of the two molecular forms of AM in the plasma and urine of patients with acute myocardial infarction. To this end, we serially measured venous, arterial and urinary AM-m and AM-Gly in 26 consecutive patients with acute myocardial infarction using our recently developed specific immunoradiometric assays (IRMAs) for total AM (AM-T ; AM-mjAM-Gly) and AM-m [23, 24] , and investigated the relationships between plasma AM-m and AM-Gly levels, clinical and haemodynamic parameters, and levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP).
METHODS

Patients
A total of 26 Japanese patients with acute myocardial infarction (21 men ; five women), aged between 41 and 80 years (meanpS. D. 64p10 years), who were admitted within 24 h of the onset of symptoms were included in the study. Of these patients, 22 were admitted within 12 h of the onset of symptoms, and the remaining four within 24 h. The diagnosis of myocardial infarction was based on the following criteria : (1) chest pain lasting longer than 30 min, (2) ST segment elevation 0.1 mV in two or more ECG leads in the same vascular territory, and (3) a subsequent rise in creatinine kinase and its myocardial band isoenzyme to at least twice the upper limit of normal. Patients with chronic obstructive lung disease, chronic renal failure (serum creatinine 260 µmol\l) or severe inflammatory disease on admission were excluded from the study.
In addition, 31 healthy normotensive subjects (16 males ; 15 females) aged between 50 and 75 years (60p6 years) who entered a 2-day hospitalized health check programme of our institute served as controls. Subjects found in the comprehensive check-up to have hypertension, cardiovascular disease, or renal, hepatic metabolic or endocrine disease were excluded. All controls were hospitalized and administered a diet containing 120-170 mmol of sodium.
Informed consent was obtained from the participants before initiation of the study. Informed consent was obtained from each patient and\or their family in the early phase of acute myocardial infarction, and again later from each patient. The experimental protocol was approved by the ethical committee of our institute.
Blood and urine sampling
Blood samples were drawn from the antecubital vein and brachial artery (with the subject in the supine position) immediately after admission, at 12, 24 and 72 h after the onset of myocardial infarction, and after 1 and 2 weeks, in order to determine the time course of changes in levels of the two molecular forms of AM, and of ANP and BNP. Urine samples were obtained at the same time as blood sampling. Urine was collected for 1 h from a urinary catheter in the acute phase of myocardial infarction. At 1 and 2 weeks after the onset of myocardial infarction, the patients drank 200-300 ml of water just after urination in the morning (08.00-09.00 hours) and urine was collected after 60 min of supine rest.
Blood was immediately divided into two tubes : a chilled glass tube containing disodium EDTA (1 mg\ml) and aprotinin (500 units\ml) for measuring plasma AM, ANP and BNP levels, and a plastic tube for measuring creatinine. Urine volume was measured, and was immediately divided into two tubes : a chilled glass tube containing disodium EDTA (1 mg\ml) and aprotinin (500 units\ml) for measuring AM-m and AM-T levels, and a plastic tube for measuring sodium and creatinine. Blood and urine were centrifuged immediately at 2000 g for 10 min at 4 mC, and plasma was stored at k80 mC until assayed.
Cardiac catheterization
Coronary angiography and left ventriculography were performed in all patients immediately after admission. All 26 patients underwent direct percutaneous transluminal coronary angioplasty, and stents were implanted in 18 of the 26 patients. The occluded coronary arteries were recanalized successfully in all patients. In 24 of the 26 patients, a Swan-Ganz catheter was inserted into the femoral vein after admission, and was maintained during the first 1-3 days to measure right atrial, pulmonary arterial and pulmonary capillary wedge pressures. Cardiac output was calculated by the thermodilution method. A second cardiac catheterization was performed on the same 24 patients 2-3 weeks after admission. At the second cardiac catheterization, the infarct-related coronary artery was patent in 23 patients. Ventricular volumes and the ejection fraction were calculated by the area\length method.
Assays for AM-m and AM-T
Both AM-m and AM-T were measured by IRMA using specific kits (AM mature RIA SHIONOGI and AM RIA SHIONOGI) developed by the Diagnostic Science Department, Shionogi Pharmaceutical Co., Ltd., Osaka, Japan [23, 24] . These assay systems each use two monoclonal antibodies against human AM : one recognizing a ring structure of human AM (in both kits), and the other recognizing the C-terminal sequence (in the AM-m kit) or AM-(25-36) (in the AM-T kit), and the assay measures human AM-m or AM-T by sandwiching it between the two antibodies without plasma extraction. The minimum detectable quantity of human AM-m or AM-T is 0.5 pmol\l for both kits. The intra-assay and inter-assay coefficients of variation for several blood samples were 4.4-8.2 % and 5.5-8.3 % respectively with the AM-m kit, and 3.4-7.3 % and 5.3-9.0 % respectively with the AM-T kit. The recovery of 5-100 pmol\l human AM added to several plasma samples was 91-118 % for the AM-m kit and 91-118 % for the AM-T kit. The recovery of 20-100 pmol\l human AM added to several urine samples was 81-92 % for the AM-m kit and 79-104 % for the AM-T kit. Reverse-phase HPLC analysis revealed that the major peak of immunoreactive AM in the plasma and urine detected by each IRMA kit for AM-m and AM-T was identical with that of synthetic human AM-(1-52) [23, 24] . The concentration of AM-Gly was calculated using the following formula : AM-Gly l AM-TkAM-m.
Assays for ANP, BNP and others
Plasma concentrations of ANP and BNP were measured using a Shiono RIA ANP and BNP assay kit (Shionogi Co., Ltd.), as reported previously [25] . Plasma creatinine was measured colorimetrically, and electrolytes were measured by the ion-selective method.
Statistical analysis
All data were expressed as meanspS.D., unless otherwise indicated. The plasma levels of AM-T, AM-Gly, AM-m, ANP, and BNP were compared over the time course of the study in patients with acute myocardial infarction using ANOVA for repeated measures. When the F value was found to be significant, the data were compared using Dunnett's test. 
RESULTS
Baseline characteristics
Baseline characteristics of the patients are summarized in Table 1 . Of the 26 patients with acute myocardial infarction, 12 had a history of hypertension, 12 had diabetes mellitus, and four had hyperlipidaemia. The mean peak plasma creatinine kinase activity was 2397p1220 units\l. The time from the onset of symptoms to the first plasma sample on admission was 8.0p5.0 h.
Time course of changes in plasma levels of AM and natriuretic peptides, and urinary excretion of AM
The time course of changes in plasma levels of AM-T, AM-Gly, AM-m, ANP and BNP, as well as the AMm\AM-T ratio, in the vein and artery are shown in Figures 1 and 2 . Plasma AM-T, AM-Gly and AM-m levels in the vein and artery were already elevated at the time of admission (Figure 1 ). Thereafter, all these molecular forms of AM reached a peak approx. 24 h after the onset of acute myocardial infarction, and remained high for 7 days compared with normal control values. Plasma AM-T levels were higher in the veins than in the arteries at acute phase ; however, AM-Gly levels were higher in the veins than in the arteries only at 24 h. Notably, plasma AM-m levels were markedly higher in the vein than in the artery throughout the time course of the study. At 14 days after the onset of acute myocardial infarction, these AM levels tended to be higher than the control values ; however, these differences did not reach statistical significance.
In contrast with plasma AM, plasma ANP levels in the vein and artery had already reached a peak value on admission, and thereafter the levels decreased gradually (Figure 2 ). There was a second small peak at 3 days, followed by a further gradual decrease. Plasma BNP levels in the vein and artery, which were also elevated on admission, were increased further at 24 h after the onset of symptoms. Thereafter the levels decreased gradually, but were still higher at 2 weeks compared with those in normal controls. In contrast with plasma AM-T and AM-m levels, plasma ANP and BNP levels were higher in the artery than in the vein throughout the time course of the study.
The time courses of changes in the urinary excretion of AM-T, AM-Gly and AM-m are shown in Figure 3 . The urinary excretion of AM-T was already elevated on admission ; it reached a peak at 12 h after the onset of symptoms, and thereafter declined gradually. At 3 days 
Figure 3 Time courses of (A) the urinary excretion of AM-T (#), AM-Gly ( ) and AM-m (=), and (B) the urinary AM-m/ AM-T ratio, in patients with acute myocardial infarction
The urinary excretion of AM-T ($), AM-Gly () and AM-m (>) (A), and the urinary AM-m/AM-T ratio ($) (B), are also shown for normal controls. Values are meanspS.E.M. Significance of differences : *P 0.01, †P 0.05 compared with control.
after the onset of symptoms, the urinary excretion of AM-T, AM-Gly and AM-m tended to be higher than the control values, but this did not reach statistical significance.
Relationships between plasma and urinary AM levels and other parameters
Plasma AM-T, AM-Gly and AM-m levels were similarly correlated with plasma BNP levels between admission and 24 h after the onset of symptoms (Figure 4) . However, plasma AM-T, AM-Gly and AM-m levels were not correlated with plasma ANP levels. Regarding the relationships with haemodynamic indices, pulmonary arterial systolic and mean pressure showed the best correlations with plasma AM-T, AM-Gly and AM-m levels ( Table 2) . The urinary excretion rates of AM-T, AM-Gly and AM-m were also similarly correlated with urinary sodium excretion from admission to 24 h after the onset of symptoms ( Figure 5 ). There were no significant relationships between plasma and urinary AM levels.
Plasma AM-m levels were well correlated with plasma AM-T and AM-Gly levels for all the data points during the study period ( Figure 6 ). Plasma AM-Gly levels were also closely correlated with plasma AM-T levels ( Figure  6 ). Urinary AM-T excretion was correlated with urinary AM-m and AM-Gly excretion for all the data points during the study period in patients with acute myocardial infarction ( Figure 7) . Urinary AM-Gly excretion was also significantly correlated with urinary AM-m excretion ( Figure 7) . The mean AM-m\AM-T ratio for all the data points during the study period in patients with acute myocardial infarction was 0.11p0.03 in the vein, which was significantly higher than that in the artery (0.06p0.03 ; P 0.0001) and significantly lower than that in the urine (0.32p0.10 ; P 0.0001). 
DISCUSSION
In the present study, we demonstrated for the first time :
(1) that levels of the two molecular forms of AM, i.e. AMGly and AM-m, were similarly elevated in early phase of acute myocardial infarction ; and (2) that AM-Gly and AM-m levels were similarly correlated with plasma BNP levels and pulmonary arterial pressure. We also demonstrated : (3) that urinary AM-Gly and AM-m levels were also elevated in the very early phase of acute myocardial infarction ; (4) that urinary excretion of AM-Gly and AM-m was correlated with urinary sodium excretion ; (5) that the AM-m\AM-T ratio was higher in the urine than in the plasma ; and (6) that there were no significant correlations between plasma and urinary AM levels. These results suggest that the synthesis of urinary and plasma AM is differently regulated (see below), although both systems are activated in early phase of acute myocardial infarction. Increased plasma and urinary AM levels may compensate heart failure in acute myocardial infarction by the physiological actions of AM, such as vasodilatation and natriuresis. We serially measured both molecular forms of AM in plasma and urine using our recently developed IRMA. According to Kitamura et al. [18] , previously reported plasma AM levels represented mean AM-T levels (being the sum of AM-m and AM-Gly), because the RIA system used polyclonal antibodies which could not distinguish between structures with or without a C-terminal amide. Kitamura et al. [18] measured plasma AM-m and AMGly levels using combined reverse-phase HPLC and two kinds of RIA system after the extraction of a large amount of plasma (10 ml). More recently, a one-step direct IRMA system for the measurement of AM-m and AM-T using different monoclonal antibodies [23, 24] has been developed. This system easily enables us to specifically measure AM-m, AM-Gly and AM-T levels within a small sample (100-200 µl) without the prior extraction of plasma. The IRMA for AM-m has no cross-reactivity Using these easy and sensitive IRMAs, we showed in the present study that plasma AM-T levels were increased in the acute phase of myocardial infarction compared with those in normal controls, which agrees well with previous reports [19] [20] [21] . We also showed that plasma AM-m and AM-Gly levels were similarly increased in the acute phase of myocardial infarction. The venous plasma AM-m\AM-T ratio was approx. 0.11 in the present study. In addition, plasma AM-m was significantly correlated with plasma AM-Gly and AM-T. These findings indicate that the major molecular form of circulating AM is AM-Gly, and that the production of AM-m and AM-Gly are similarly regulated under pathological conditions such as acute myocardial infarction. Although the mechanism behind the increase in AM in acute myocardial infarction is still not fully understood, it is well known that AM synthesis in vascular endothelial cells and vascular smooth muscle cells is promoted by many kinds of cytokines, such as interleukin-1β and tumour necrosis factor-α [26, 27] , both of which increase in parallel with myocardial tissue damage after myocardial infarction [28, 29] . These results suggest that the disordered peripheral vascular bed contributes to the increase in AM levels in acute myocardial infarction.
We found that venous AM-T levels were slightly, but significantly, higher than arterial AM-T levels in the acute phase of myocardial infarction. However, venous AM-Gly levels were higher than arterial AM-Gly levels only at 24 h after the onset of myocardial infarction. Interestingly, venous AM-m levels were apparently higher than arterial AM-m levels throughout the time course of the study. These findings are consistent with the hypothesis that AM-m is produced in the peripheral circulation and is extracted in the pulmonary circulation. Previously, an autoradiographic study showed that an intravenous injection of "#&I-AM was avidly taken up by the lung [30] , suggesting that the lung has abundant binding sites for AM. In addition, AM binding sites and AM receptor mRNA were reported to be highly concentrated in the lung [31, 32] . Indeed, several studies have shown that plasma AM was partially metabolized in the pulmonary circulation in patients with pulmonary hypertension and ischaemic heart disease [15, 16, 33] . Thus the observed slight extraction of plasma AM-T from vein to artery may be due to the extraction of AM-m in the pulmonary circulation in patients with myocardial infarction. Although the pathophysiological significance of extracted AM in the pulmonary circulation remains unknown, several studies have demonstrated that AM markedly dilates pulmonary vessels in animals and humans [34] [35] [36] . Taken together, these findings suggest the following : (1) AM-m is produced in and secreted by the peripheral circulation ; (2) the main site of clearance of circulating AM-m is the lung ; and (3) circulating AM-m may help to attenuate the increased pulmonary vascular resistance in acute myocardial infarction.
In the present study we showed that urinary AM levels were increased in the acute phase of myocardial infarction. Urinary excretion of AM-T, AM-m and AMGly reached a peak at 12 h after the onset of myocardial infarction. Since the peak concentrations in plasma and urine were similar, the cytokines that stimulate the synthesis of plasma AM may also increase the synthesis of renal AM. To date, the origin of urinary AM is not fully understood. A previous study showed that AM is present in human urine and that AM levels are several times higher in urine than in plasma, suggesting that urinary AM is produced in the kidney. An autoradiographic study involving a venous injection of "#&I-AM revealed that intense "#&I-AM uptake was observed in the proximal tubules [30] . These findings indicate that plasma AM filtered by the glomerulus is almost totally re-absorbed by the proximal tubular cells. In addition, an immunohistochemical study showed that AM stained strongly in the renal distal tubules and collecting duct cells [37] , and AM mRNA expression was observed in these cells by reverse transcrption-PCR methods [38] .
Furthermore, previous studies showed that AM has renal actions such as diuresis and natriuresis, and also increases the glomerular filtration rate and renal blood flow. Indeed, there were significant correlations between urinary AM levels and urinary sodium excretion in the present study. Taken together, these findings suggest that urinary AM is derived from renal tubular cells rather than from the plasma, and that urinary AM may be involved in the regulation of sodium excretion. Interestingly, the present study showed that the AM-m\AM-T ratio was apparently higher in urine than in plasma. Although the exact mechanism remains unknown, one possible explanation is that amidation efficiency is higher in the kidney than in the vascular vessels. Further studies are necessary to elucidate the exact mechanism involved.
The present study is subject to certain limitations. First, the effects of medication on plasma and urinary AM levels in patients with acute myocardial infarction remain unknown. A previous study reported that antihypertensive therapy did not affect plasma AM levels in patients with essential hypertension [39] , whereas other investigators reported that the elevated plasma levels of AM in patients with malignant hypertension and heart failure decreased significantly after medical treatment [10, 40] . Thus medication might modulate plasma AM levels. In addition, recent studies revealed that angiotensin-converting enzyme inhibitors significantly decreased myocardial AM levels in acute myocardial infarction and in aortic banding in rats [41, 42] . Since 24 of our 26 patients were taking angiotensin-converting enzyme inhibitors, we cannot rule out the possibility that the present study might have underestimated plasma or urinary AM levels. Secondly, the effects of disease history, such as hypertension, diabetes mellitus and hyperlipidaemia, on plasma and urinary AM levels in patients with acute myocardial infarction remain unknown. Plasma AM levels are reported to be higher in patients with hypertension [12, 13] and diabetes mellitus [43] . However, in the present study there were no significant differences in peak plasma AM-T levels between patients with and without these diseases (hypertension, 32.1p9.2 compared with 33.2p 12.6 pmol\l ; diabetes mellitus, 33.0p14.9 compared with 32.4p9.6 pmol\l ; hyperlipidaemia, 33.3p9.8 compared with 32.6p11.5 pmol\l ; all not significant). However, since the number of patients in our study was relatively small, further studies are necessary in order to answer this question. Thirdly, to the best of our knowledge, no reports have investigated the effects of gender on plasma or urinary AM levels. In the present study there were no significant differences in plasma AM levels between males and females in the normal control group. In addition, there were no differences between males and females in peak plasma AM levels following acute myocardial infarction (34.3p11.3 and 26.2p7.2 pmol\l respectively ; not significant). However, in view of our relatively small number of patients, further studies are required to examine the effects of gender on plasma AM levels.
In conclusion, we have demonstrated that plasma and urinary AM levels are increased in the acute phase of myocardial infarction. Since AM exerts potent cardiovascular and renal effects, increased AM levels in plasma and urine may be involved in the defence mechanism against further elevations in peripheral and pulmonary vascular resistance and oliguria in acute myocardial infarction.
